AALL15P1 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688 NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Brief description of study

If your child is less than 1 year old and has been diagnosed with Acute Lymphoblastic Leukemia (ALL) a type of cancer that occurs in the blood, your child may qualify for this study evaluating a drug called azacitidine when added to standard chemotherapy. The main goal of this study is to see how well the addition of a drug called azacitidine to standard chemotherapy is tolerated in subjects less than 1 year old.


Clinical Study Identifier: s17-00488
ClinicalTrials.gov Identifier: NCT02828358
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.